Commercial Services and Supplies
Company Overview of Juvenile Diabetes Research Foundation International Inc.
Juvenile Diabetes Research Foundation International Inc. (JDRF) is a not-for-profit organization that focuses on juvenile diabetes cure research and development services. The organization offers grants for diabetes clinical trials to laboratories, educational institutions, and pharmaceutical and medical research companies. JDRF was founded in 1970 and is headquartered in New York City with an additional office in Houston, Texas.
120 Wall Street
New York, NY 10005-4001
Founded in 1970
Key Executives for Juvenile Diabetes Research Foundation International Inc.
Executive Vice President for Development and Chief Operating Officer
Vice President-Customer Services
Executive Vice President for Research
Senior Vice President of Development and Field Operations
Compensation as of Fiscal Year 2017.
Juvenile Diabetes Research Foundation International Inc. Key Developments
JDRF and Cam Med Partner to Develop Flexible Patch Pump for Automated Insulin Delivery Systems
Feb 5 18
JDRF and Cam Med LLC announced a new Industry Development and Discovery Partnership to develop a user-centric insulin pump for next-generation artificial pancreas systems. This funding commitment from JDRF will enable Cam Med to further the development of its innovative Evopump, an ultra-thin and flexible, bandage-like patch pump. Since JDRF launched the Artificial Pancreas Project more than a decade ago, significant progress has been made in automating insulin delivery. However, the bulkiness of automated insulin delivery devices remains a challenge and may be a factor inhibiting wide-scale adoption, especially in children where skin "real estate" is at a premium. The goal of this collaboration is to accelerate the development of Cam Med's conformable and small-footprint Evopump, which would represent a substantial improvement over existing delivery systems for both pediatric and adult users. T1D is an autoimmune disease that occurs when a person's pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body's immune system. T1D must be managed with the lifelong use of insulin—either via injection or insulin pump.
JDRF Partners with EOFlow to Develop Wearable Automated Insulin Delivery System for People with Type 1 Diabetes
Jan 25 18
JDRF announced a new Industry Development and Discovery Partnership supporting South Korea's EOFlow Co. Ltd. in the development of a wearable, disposable automated insulin delivery patch device for people with T1D. EOFlow recently received Korean Ministry of Food and Drug Safety (MFDS) approval on its wearable insulin pump system, EOPatch. The product incorporates a proprietary electroosmotic pumping technology which allows it to be smaller and lighter and the company plans to build on this strength to create a small, light and wearable automated insulin delivery device suitable for children's use. EOFlow will use the funding to develop and run clinical studies on the wearable device, which consists of an insulin pump and an integrated continuous glucose sensor, which is run by a closed-loop program that autonomously regulates the blood glucose level with minimal user input. This is the first time JDRF is granting funds to EOFlow for research and is also the first time that JDRF is funding a company in Korea.
Juvenile Diabetes Research Foundation International Inc. Presents at Redefining Early Stage Investments Conference, Jan-09-2018
Jan 8 18
Juvenile Diabetes Research Foundation International Inc. Presents at Redefining Early Stage Investments Conference, Jan-09-2018 . Venue: Marines’ Memorial Club & Hotel, 609 Sutter St., San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries